Li XL, Li T, Du QC, Yang L, He KL. Effects of angiotensin receptor blockers and angiotensin-converting enzyme inhibitors on COVID-19. World J Clin Cases 2021; 9(20): 5462-5469 [PMID: 34307600 DOI: 10.12998/wjcc.v9.i20.5462]
Corresponding Author of This Article
Kun-Lun He, MD, Chief Physician, Translational Medical Research Center, Key Laboratory of Ministry of Industry and Information Technology of Biomedical Engineering and Translational Medicine, Medical Innovation Research Division of Chinese PLA General Hospital, No. 28 Fuxing Road, Haidian District, Beijing 100853, China. kunlunhe@plagh.org
Research Domain of This Article
Cardiac & Cardiovascular Systems
Article-Type of This Article
Retrospective Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Cases. Jul 16, 2021; 9(20): 5462-5469 Published online Jul 16, 2021. doi: 10.12998/wjcc.v9.i20.5462
Effects of angiotensin receptor blockers and angiotensin-converting enzyme inhibitors on COVID-19
Xiao-Long Li, Tao Li, Qi-Cong Du, Li Yang, Kun-Lun He
Xiao-Long Li, Department of Diagnostic Radiology, PLA General Hospital, Beijing 100853, China
Tao Li, Li Yang, Department of Radiology, The First Medical Center of PLA General Hospital, Beijing 100853, China
Qi-Cong Du, Department of Diagnostic Radiology, The First Medical Center of PLA General Hospital, Beijing 100853, China
Kun-Lun He, Translational Medical Research Center, Key Laboratory of Ministry of Industry and Information Technology of Biomedical Engineering and Translational Medicine, Medical Innovation Research Division of Chinese PLA General Hospital, Beijing 100853, China
Author contributions: Li XL, Li T and Du QC contribute equally to this article and should be considered as co-first authors; Li XL and Du QC performed the operation; Li XL and He KL designed this retrospective study; Du QC and Yang L wrote this paper; Li T was responsible for sorting the data.
Institutional review board statement: The study was reviewed and approved by the Institutional Review Board of Huoshenshan Hospital, Wuhan, China (Approval No. HSSLL019).
Informed consent statement: Patients were not required to give informed consent to the study because the analysis used anonymous clinical data that were obtained after each patient agreed to treatment by written consent.
Conflict-of-interest statement: The authors declare that they have no competing interests.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Kun-Lun He, MD, Chief Physician, Translational Medical Research Center, Key Laboratory of Ministry of Industry and Information Technology of Biomedical Engineering and Translational Medicine, Medical Innovation Research Division of Chinese PLA General Hospital, No. 28 Fuxing Road, Haidian District, Beijing 100853, China. kunlunhe@plagh.org
Received: April 6, 2021 Peer-review started: April 6, 2021 First decision: April 28, 2021 Revised: April 30, 2021 Accepted: May 24, 2021 Article in press: May 24, 2021 Published online: July 16, 2021 Processing time: 91 Days and 22.1 Hours
Abstract
BACKGROUND
The World Health Organization reported that 28637952 people worldwide had been infected with severe acute respiratory syndrome coronavirus 2, the causative agent of coronavirus disease 2019 (COVID-19), by September 13.
AIM
The aim was to investigate whether long-term use of renin-angiotensin-aldosterone system (RAAS) inhibitors for the treatment of hypertension aggravates the performance of COVID-19 patients with hypertension.
METHODS
This was a retrospective analysis of lung computed tomography (CT) data and laboratory values of COVID-19 patients with hypertension who were admitted to Huoshenshan Hospital, Wuhan, Hubei Province, between February 18 and March 31, 2020. Patients were divided into two groups. Group A included 19 people who were long-term users of RAAS inhibitors for hypertension; and group B included 28 people who were randomly selected from the database and matched with group A by age, sex, basic diseases, and long-term use of other antihypertensive drugs. All patients underwent a series of CT and laboratory tests. We compared the most severe CT images of the two groups and the laboratory examination results within 2 d of the corresponding CT images.
RESULTS
The time until the most severe CT images from the onset of COVID-19 was 30.37 ± 14.25 d group A and 26.50 ± 11.97 d in group B. The difference between the two groups was not significant (t = 1.01, P = 0.32). There were no significant differences in blood laboratory values, C-reactive protein, markers of cardiac injury, liver function, or kidney function between the two groups. There was no significant difference in the appearance of the CT images between the two groups. The semiquantitative scores of each involved lobe were 11.84 ± 5.88 in group A and 10.36 ± 6.04 group B. The difference was not significantly different (t = 0.84, P = 0.41).
CONCLUSION
Chest CT is an important imaging tool to monitor the characteristics of COVID-19 and the degree of lung injury. Chronic use of RAAS inhibitors is not related to the severity of COVID-19, and it does not worsen the clinical process.
Core Tip: We investigated whether the use of renin-angiotensin-aldosterone system inhibitors by coronavirus disease 2019 patients with hypertension aggravated the severity of pneumonia by comparing the differences in computed tomography images.
